GlassScriptPhysician profile
Michelle Martin
NPI 1144741661
$582.28
in general payments reported to CMS, 2019-2025
19 companies · $60.93 in 2025
The $60.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $280 · 2023: $98.13 · 2024: $143 · 2025: $60.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $153.93 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $69.06 | 2022-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $55.97 | 2022-2025 | Breztri |
| Merck Sharp & Dohme LLC | $42.92 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $28.03 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $20.10 | 2022 | |
| Axsome Therapeutics, INC. | $19.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.60 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $17.46 | 2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $16.74 | 2022 | |
| Abbvie INC. | $16.46 | 2022 | |
| Amgen INC. | $16.26 | 2024 | Repatha, Otezla |
| Pfizer INC. | $16.04 | 2024 | |
| Novo Nordisk INC | $15.80 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.67 | 2023 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $14.00 | 2024 | Nuzyra |
| Glaxosmithkline, LLC. | $12.21 | 2022 | |
| Organon LLC | $4.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.